A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors
Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...
Հիմնական հեղինակներ: | Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD |
---|---|
Ձևաչափ: | Հոդված |
Լեզու: | English |
Հրապարակվել է: |
SAGE Publishing
2022-09-01
|
Շարք: | Cancer Control |
Առցանց հասանելիություն: | https://doi.org/10.1177/10732748221130576 |
Նմանատիպ նյութեր
-
Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
: Hiroki Hata MS, և այլն
Հրապարակվել է: (2020-12-01) -
Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
: Hideo Oishi, MD, և այլն
Հրապարակվել է: (2020-10-01) -
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
: Arthur E. Frankel MD, և այլն
Հրապարակվել է: (2019-04-01) -
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
: Taichi Miyawaki, MD, և այլն
Հրապարակվել է: (2020-06-01) -
Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
: Bilguun Erkhem-Ochir, MD, և այլն
Հրապարակվել է: (2021-03-01)